2017-03-15,Mateon Therapeutics Announces Initial Data From Third Cohort Of Phase 1b Study Of OXi4503 In Relapsed/Refractory AML
2017-03-08,Mateon Therapeutics To Present At 29th Annual ROTH Conference
2017-02-13,Mateon Therapeutics Announces Initial Pre-clinical Data On Combination Of CA4P With Checkpoint Inhibitors
2017-02-07,Mateon Therapeutics To Present At BIO CEO & Investor Conference On February 13, 2017
2017-01-20,Mateon Therapeutics To Present Data On Study OX4218 In Neuroendocrine Tumors At ASCO Gastrointestinal Cancers Symposium
2016-12-08,OTC Markets Group Welcomes Mateon Therapeutics To OTCQX
2016-12-07,Mateon Common Stock To Trade On OTCQX Beginning On December 8, 2016
2016-12-06,Mateon Announces Presentation Of OXi4503 AML Study Data At 58th Annual Meeting Of American Society Of Hematology
2016-11-14,Mateon Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-11,Mateon Announces Adjournment Of Special Meeting Of Stockholders
2016-10-31,Mateon Announces Presentation Of CA4P Posters At Meeting Of The International Gynecologic Cancer Society
2016-10-27,Mateon Expands Board Of Directors With The Appointments Of Donald R. Reynolds And Bobby W. Sandage, Jr., Ph.D.
2016-10-10,Mateon Announces Issuance Of US Patent For Cathepsin Inhibition
2016-09-26,Mateon Announces Collaboration With US Oncology Research To Participate In Phase 2/3 FOCUS Study
2016-09-20,Mateon Therapeutics To Present At The Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
2016-09-07,Mateon Therapeutics To Present At The 18th Annual Rodman And Renshaw Global Investment Conference In New York On September 12, 2016
2016-08-03,Mateon Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-21,Mateon Announces Enrollment Of First Patient In Phase 2 Portion Of PAZOFOS Study In Recurrent Ovarian Cancer
2016-06-23,Mateon Announces Initiation Of FOCUS Study In Platinum-Resistant Ovarian Cancer
,
,
,
,
,
2017-03-15,Mateon Therapeutics Announces Initial Data From Third Cohort Of Phase 1b Study Of OXi4503 In Relapsed/Refractory AML
2017-03-08,Mateon Therapeutics To Present At 29th Annual ROTH Conference
2017-02-13,Mateon Therapeutics Announces Initial Pre-clinical Data On Combination Of CA4P With Checkpoint Inhibitors
2017-02-07,Mateon Therapeutics To Present At BIO CEO & Investor Conference On February 13, 2017
2017-01-20,Mateon Therapeutics To Present Data On Study OX4218 In Neuroendocrine Tumors At ASCO Gastrointestinal Cancers Symposium
2016-12-08,OTC Markets Group Welcomes Mateon Therapeutics To OTCQX
2016-12-07,Mateon Common Stock To Trade On OTCQX Beginning On December 8, 2016
2016-12-06,Mateon Announces Presentation Of OXi4503 AML Study Data At 58th Annual Meeting Of American Society Of Hematology
2016-11-14,Mateon Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-11,Mateon Announces Adjournment Of Special Meeting Of Stockholders
2016-10-31,Mateon Announces Presentation Of CA4P Posters At Meeting Of The International Gynecologic Cancer Society
2016-10-27,Mateon Expands Board Of Directors With The Appointments Of Donald R. Reynolds And Bobby W. Sandage, Jr., Ph.D.
2016-10-10,Mateon Announces Issuance Of US Patent For Cathepsin Inhibition
2016-09-26,Mateon Announces Collaboration With US Oncology Research To Participate In Phase 2/3 FOCUS Study
2016-09-20,Mateon Therapeutics To Present At The Ladenburg Thalmann 2016 Healthcare Conference on September 27, 2016
2016-09-07,Mateon Therapeutics To Present At The 18th Annual Rodman And Renshaw Global Investment Conference In New York On September 12, 2016
2016-08-03,Mateon Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-21,Mateon Announces Enrollment Of First Patient In Phase 2 Portion Of PAZOFOS Study In Recurrent Ovarian Cancer
2016-06-23,Mateon Announces Initiation Of FOCUS Study In Platinum-Resistant Ovarian Cancer
,
,
,
,
,
